Protection against ventricular fibrillation by the PAF antagonist, BN- 50739, involves an ischaemia-selective mechanism

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 3, 1999, Pages 394-401

  Baker, Kathryn E ^a   Curtis, Michael J ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antiarrhythmic; BN 50739; Heart; Ischaemia selective; Myocardial ischaemia; Platelet activating factor; Ventricular fibrillation

Indexed keywords

6 (2 CHLOROPHENYL) 9 [(3,4 DIMETHOXYPHENYL)THIOMETHYLTHIOCARBONYL] 4,7,8,10 TETRAHYDRO 1 METHYLPYRIDO[4',3':4,5]THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART RATE; HEART VENTRICLE FIBRILLATION; MALE; NONHUMAN; PR INTERVAL; PRIORITY JOURNAL; QT INTERVAL; RAT;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; AZEPINES; DISEASE MODELS, ANIMAL; MALE; MYOCARDIAL ISCHEMIA; PERFUSION; PLATELET ACTIVATING FACTOR; PROTECTIVE AGENTS; RATS; RATS, WISTAR; TRIAZOLES; VASODILATION; VENTRICULAR FIBRILLATION;

EID: 0032864575     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199909000-00012     Document Type: Article

References (47)

1. Campbell RWF, Murray A, Julian DG. Ventricular arrhythmias in first 12 hours of acute myocardial infarction: natural history study. Br Heart J 1981;46:351.
2. Rosen MR. Cardiac arrhythmias and anti-arrhythmic drugs: recent advances in our understanding of mechanism. J Cardiovasc Electrophysiol 1995;6:868-79.
3. Vlay SC. Ventricular arrhythmias. In: Vlay SC, ed. A practical approach to cardiac arrhythmias. London: Little, Brown, 1996: 148-83.
4. Speilman S, Kay UR, Morganroth J, Horowitz LN, Greenspan AM. Drug therapy in high risk patients following acute myocardial infarction - results of Timolol, Encainide and Sotolol Trial. Circ Res 1985;72:15.
5. Akhtar M, Breithardt G, Camm, et al. CAST and beyond: implications of Cardiac Arrhythmia Suppression Trial. Circulation 1990;81:1123.
6. Waldo AL, Camm AJ, Deruyter H, et al. Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
7. Curtis MJ, Pugsley MK, Walker MJA. Endogenous chemical mediators of ventricular arrhythmias in ischaemic heart disease. Cardiovasc Res 1993;27:703-19.
8. Braquet P, Touqui L, Shen TY, Vargaftig BB. Perspectives in platelet activating factor research. Pharmacol Rev 1987;39:97-145.
9. Chakrabarty S, Thomas P, Sheridan DJ. Contribution of platelets and platelet activating factor PAF, to the arrhythmogenic, haemodynamic and necrotic effects of acute myocardial ischaemia. Eur Heart J 1991;12:583-9.
10. Benveniste J, Boullet C, Brink C, Labat C. The actions of PAF-acether platelet activating factor on guinea pig isolated heart preparations. Br J Pharmacol 1983;80:81-3.
11. Kenzora JL, Perez JE, Bergmann SR, Lange LG. Effects of acetyl glycerol ether of phosphorylcholine platelet activating factor on ventricular preload, afterload, and contractility in dogs. J Clin Invest 1984;74:1193-203.
12. Toyofuku T, Kobayashi T, Koyama S, Kusama S. Pulmonary vascular response to platelet activating factor in conscious sheep. Am J Physiol 1988;255:H434-40.
13. Sirois MG, Jancar S, Plante GE, Sirois P. PAF increases protein extravasation in selected rat tissues. In: Braquet P, ed. Ginkolides: chemistry, biology pharmacology and clinical perspectives. Vol 2. Paris: JR Prous Science Publishers, 1989:255-68.
14. Halonen M, Palmer JD, Lohman IC, Mcmanus LM, Pinckard RN. Respiratory and circulatory alterations induced by acetyl, glyceryl ether phosphorylcholine, a mediator of IGE anaphylaxis in rabbit. Am Rev Respir Dis 1981;122:915-24.
15. Mueller HW, Haught CA, McNatt JM, et al. Measurement of platelet activating factor in a canine model of coronary thrombosis and in endarterectomy samples from patients with advanced coronary artery disease. Circ Res 1995;77:54-63.
16. Koller M, Hilger RA, Konig W. Effect of PAF receptor antagonist SM-12502 on human platelets. Inflammation 1996;20:71-85.
17. 4. Br J Pharmacol 1986;88:595-605.
18. Robertson DA, Genovese A, Levi R. Negative inotropic effect of platelet activating factor on human myocardium: a pharmacological study. J Pharmacol Exp Ther 1987;243:834-9.
19. Flores NA, Sheridan DJ. Electrophysiological and arrhythmogenic effects of platelet activating factor during normal perfusion, myocardial ischaemia and reperfusion in the guinea pig. Br J Pharmacol 1990;101:734-8.
20. Stahl GI, Terashita ZI, Lefer AM. Role of PAF in propagation of cardiac damage during myocardial ischaemia. J Pharmacol Exp Ther 1988;244:898-904.
21. Zimmerman GA, McIntyre TM, Prescott SM. Production of platelet activating factor by human vascular endothelial cells: evidence for a requirement for specific agonists and modulation by prostacyclin. Circulation 1985;72:718-27.
22. Montrucchio G, Alloatti G, Tetta C, et al. Release of platelet activating factor from ischaemic-reperfused rabbit heart. Am J Physiol 1989;256:H1238-46.
23. Salinas P, Dolores Perez M, Fernandez-Sanpablo R, Fernandez-Gallardo S, Sanchez-Crespo M, Barrigon S. Lack of platelet activating factor release on acute myocardial ischaemia in the isolated interventricular septum of rabbit heart. Eur J Pharmocol 1995;293: 65-70.
24. Annable CR, Mcmanus LR, Carey KR, Pinckard RN. Isolation of platelet activating factor from ischaemic baboon myocardium. Fed Proc 1985;44:1271.
25. Koltai M, Tosaki A, Hosford D, Esanu A, Braquet P. Effect of BN-50739, a new platelet activating factor antagonist, on ischaemia induced ventricular arrhythmias in isolated working rat hearts. Cardiovasc Res 1991;25:391-7.
26. Curtis MJ, Hearse DJ. Ischaemia-induced and reperfusion-induced arrhythmias differ in their sensitivity to potassium: implications for mechanism of initiation and maintenance of ventricular fibrillation. J Mol Cell Cardiol 1989;21:21-40.
27. Curtis MJ. Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia-induced ventricular fibrillation. Cardiovasc Res 1998;39:194-215.
28. Avkiran M, Curtis MJ. Independent dual perfusion of left and right coronary arteries in isolated rat hearts. Am J Physiol 1991;261: H2082-90.
29. Curtis MJ, Hearse DJ. Reperfusion-induced arrhythmias are critically dependent upon occluded zone size: relevance to the mechanism of arrhythmogenesis. J Mol Cell Cardiol 1989;21:625-37.
30. Pabla R, Curtis MJ. Effect of endogenous nitric oxide on cardiac systolic and diastolic function during ischaemia and reperfusion in the rat isolated perfused heart. J Mol Cell Cardiol 1996;28:2111-21.
31. Walker MJA, Curtis MJ, Hearse DJ, et al. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia. Infarction, and reperfusion. Cardiovasc Res 1988;22:447-55.
32. to blockade? J Cardiovasc Pharmacol 1991;18:455-6.
33. Ridley PD, Yacoub MH, Curtis MJ. A modified model of global ischaemia: application to the study of syncytial mechanisms of arrhythmogenesis. Cardiovasc Res 1992;26:313-23.
34. Yue TL, Rabinova R, Farhat M, Feuerstein G. Pharmacologic profile of BN-50739, a new PAF antagonist, in-vitro and in-vivo. Prostaglandins 1990;39:469-80.
35. Hwang SB. Specific receptors of platelet activating factor, receptor heterogenicity and signal transduction mechanisms. J Lipid Med 1990;2:123-58.
36. Izumi T, Shimizu T. Platelet activating receptor: gene expression and signal transduction. Biochim Biophys Acta 1995;1259:317-33.
37. Chao W, Olson MS. Platelet activating factor: receptors and signal transduction. Biochem J 1993;292:617-29.
38. Predescu D, Ihida K, Predescu S, Palade GE. The vascular distribution of the platelet activating factor receptor. Eur J Cell Biol 1996;69:86-98.
39. Curtis MJ, MacLeod BA, Walker MJA. Models for the study of arrhythmias in myocardial ischaemia and infarction: the use of the rat. J Mol Cell Cardiol 1987;19:399-419.
40. Maxwell MP, Hearse DJ, Yellon DM. Species variation in the coronary circulation during regional myocardial ischaemia: a critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc Res 1987;21:737-46.
41. Curtis MJ, Baczko I, Baker KE. The ECG in man and laboratory animals: recording methods, analysis and interpretation. In: Walker MJA, Pugsley MK, eds. Methods in cardiac electrophysiology. Basel: CRC Press, 1997:133-58.
42. Rees SA, Curtis MJ. Which cardiac potassium channel subtype is the preferable target for suppression of ventricular arrhythmias? Pharmacol Ther 1996;69:199-217.
43. Yamanaka S, Miura K, Yukimura T, Okumura M, Yamamoto K. Putative mechanism of hypotensive action of platelet activating factor in dogs. Circ Res 1992;70:893-900.
44. 1 blocker, RP58866, assessed using the rat dual coronary perfusion model. J Mol Cell Cardiol 1995;27:2595-606.
45. Grover GJ, Dzwonezyk S, Parham CS, Sleph PG. The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anaesthetised dogs. Cardiovasc Drugs Ther 1990;4:465-74.
46. 1 blockade, a new antiarrhythmic mechanism: effect of RP58866 on ventricular arrhythmias in rat, rabbit and primate. Circulation 1993;87:1979-89.
47. to blocker increase coronary flow independent of effects on heart rate, QT interval, and ischaemia-induced ventricular fibrillation in rats. J Cardiovasc Pharmacol 1993;22:343-49.